Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.

Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.

Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.

Robot-assisted radical hysterectomy reduced mostly low-grade intraoperative complications vs open surgery in early-stage cervical cancer.

Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.

The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.

Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.